Necroptosis is a regulated form of cell death involved in several disease models including in particular liver diseases. Receptor-interacting protein kinases, RIPK1 and RIPK3, are the main serine/threonine kinases driving this cell death pathway. We screened a noncommercial, kinase-focused chemical library which allowed us to identify Sibiriline as a new inhibitor of necroptosis induced by tumor necrosis factor (TNF) in Fas-associated protein with death domain (FADD)-deficient Jurkat cells. Moreover, Sib inhibits necroptotic cell death induced by various death ligands in human or mouse cells while not protecting from caspase-dependent apoptosis. By using competition binding assay and recombinant kinase assays, we demonstrated that Sib is a rather specific competitive RIPK1 inhibitor. Molecular docking analysis shows that Sib is trapped closed to human RIPK1 adenosine triphosphate-binding site in a relatively hydrophobic pocket locking RIPK1 in an inactive conformation. In agreement with its RIPK1 inhibitory property, Sib inhibits both TNF-induced RIPK1-dependent necroptosis and RIPK1-dependent apoptosis. Finally, Sib protects mice from concanavalin A-induced hepatitis. These results reveal the small-molecule Sib as a new RIPK1 inhibitor potentially of interest for the treatment of immune-dependent hepatitis.
Introduction
Excessive hepatocyte cell death has been identified as a central pathophysiological mechanism in both acute and chronic liver injuries, involving mostly cell death by apoptosis and necrosis (oncosis) [1] . More recently, necroptosis, a specific form of regulated necrosis, has also been implicated in liver disease models [2, 3] . Necroptosis is a caspase-independent nonapoptotic backup cell death mechanism initiated upon blockade of apoptosis [4] . This cell death pathway is dependent on serine/threonine receptor-interacting protein kinases, RIPK1 and RIPK3, and a pseudokinase MLKL (mixed-lineage kinase domain-like) (see for review [5] ). Moreover, it is inhibited by necrostatin-1 (Nec-1), the first small tryptophan-based molecule inhibitor of RIPK1 kinase activity [4, 6] .
Necroptosis may occur in response to various stimuli [5] . The tumor necrosis factor (TNF)-induced necroptosis pathway has been most intensively studied. Upon TNF stimulation when caspase-8 is inhibited or absent [7, 8] , RIPK1 in complex II recruits RIPK3, resulting in autophosphorylation and activation of the latter. Caspase-8 and FLIP L in complex II negatively regulates RIPK1 and RIPK3 by proteolysis [9] . Then, these kinases interact with each other via their RIP homotypic interaction motif (RHIM) domains promoting necrosome formation [10] , recruitment and phosphorylation of MLKL [11, 12] which in turn oligomerizes [13] and is recruited to negatively charged phosphoinositolphosphates [14] , causing loss of plasma membrane integrity [15] . Necroptosis contributes to the pathogenesis of several inflammatory diseases including ischemic reperfusion injury, acute pancreatitis, sepsis, neurodegeneration, and viral infection [16] . Although the contribution of necroptosis in liver disease is still an open question [17] , some studies reported that necroptosis is also involved in inflammatory-driven liver diseases. On one hand, RIPK3-deficient mice are protected from ethanol-and acetaminophen (APAP)-induced hepatocyte injury or nonalcoholic steatohepatitis (NASH) [18] [19] [20] . On the other hand, RIPK3 expression is increased in liver biopsies of chronic ethanol-fed mice, alcoholic liver disease patients, NASH patients, or patients with other chronic liver diseases (hepatitis B and C) [18, 20, 21] . Furthermore, Nec-1 or Nec-1s protects against APAPor concanavalin A-induced hepatoxicity [22] [23] [24] [25] . To date, the only possible candidate to be used in the clinic would be the anticancer drug B-RafV600E Dabrafenib which besides mutant Raf targeting also inhibits RIPK3 and alleviates APAP-induced liver injury [26] . Altogether these data suggest that targeting necroptosis could be a novel therapeutic strategy for liver diseases.
Nec-1 (5-((1H-indol-3-yl)methyl)-3-methyl-2-thioxoimidazolidin-4-one) was identified in a phenotype screen for small molecule inhibiting TNF-induced necroptosis in human monocytic U937 cells [4, 27] , and further was shown to be an allosteric inhibitor of RIPK1 kinase [6] . However, Nec-1 is not specific for RIPK1 because its chemical scaffold is similar to methyl-thiohydantoin-trytophan, an inhibitor of indoleamine 2,3-dioxygenase (IDO), an immune regulator [28] . Structure-activity relationship (SAR) study revealed that small substituent Cl at the position 7 of the indole ring leads to the compound necrostatin-1s (Nec-1s) [27] having an increased selective RIPK1 inhibitory activity [29] and lacking IDO inhibitory activity [28] . However, necrostatins have poor pharmacokinetic properties. More recently, other classes of compounds were described such as the 1-aminoisoquinolines, 5-phenylpyrrolo [2,3-b] pyridines, 5-arylpyrrolo[2,3-b] pyridines, furo [2,3-d] pyrimidines, analogs of Bcr-Abl inhibitor ponatinib, PN10 (fusion of the scaffold of ponatinib and Nec-1s), the benzo[b]1,4]oxazepin-4-ones, the compound GSK'963, and the N-benzyl-N-hydroxy-2,2-dimethylbutanamide [30] [31] [32] [33] [34] [35] [36] . The previously described biological activities validate kinase RIPK1 as a promising therapeutic target for discovering new compounds to treat various human disorders [37] . The quest for an optimized clinical candidate is still in progress with the synthesis of the firstin-class RIP1 kinase-specific inhibitor (GSK2982772) [38] and will benefit from the description of new potent RIPK1 inhibitors.
In order to find new inhibitors of RIPK1, we screened an in-house kinase-focused library of small chemical compounds (the ReCC, Roscoff essential Chemical Collection, Roscoff, France) using a phenotypic screen based on the inhibition of TNF-induced necroptosis in human FADD-deficient Jurkat T cells (in vitro model described in Ref. [39] ). Among 1015 tested compounds, 4-(1H-pyrrolo [2,3-b] pyridin-2-yl) phenol [Sibiriline (Sib)] was selected as the best hit. Interestingly, we describe here the biochemical properties and both in vitro and in vivo effects of this new pyrrolo [2,3-b] pyridine-based derivative as a potent RIPK1 inhibitor/necroptosis inhibitor. Our results indicate that the kinase activity of RIPK1 is dosedependently affected by Sib. In silico molecular modeling and docking studies reveal that Sib interacts with RIPK1 kinase domain in a hydrophobic 'back' pocket [32] , between the gatekeeper and the DFG (DLG in RIPK1) motif, adjacent to the adenosine triphosphate (ATP)-binding site, thus locking RIPK1 in an inactive DLG out conformation. Finally, to assess the therapeutic efficacy of Sib in liver diseases, we studied its effects in concanavalin A-induced hepatitis in C57Bl/6 mice. This acute hepatitis is a mouse model of immune-mediated liver injury [40] . A single intraperitoneal injection of Sib protects mice from liver injury induced by concanavalin A, and therefore, reveals Sib as a promising new chemical scaffold of RIPK1 inhibitor, with a straightforward, high-yielding synthesis, which is effective in the treatment of the preclinical model of immune-dependent hepatitis.
Results

Sibiriline is a new necroptosis inhibitor
To identify novel necroptosis inhibitors, we screened a noncommercial, kinase-focused chemical library of 1015 compounds for their ability to block TNFinduced necroptosis in FADD-deficient human Jurkat cells (Fig. 1A ). These compounds were tested at the concentration of 10 lM and compared to the wellcharacterized RIPK1 inhibitor necrostatin-1 (Nec-1). Among the tested drugs, Sib stood out as the most potent molecule at rescuing cells from necroptotic cell death, whereas Sib-i came out as its inactive analog (Fig. 1B) . Similar to Nec-1 (EC 50 = 0.3 lM), Sib efficiently blocked necroptotic death in FADD-deficient Jurkat cells in a concentration-dependent manner with an EC 50 value of 1.2 lM (Fig. 1C) . The inactive derivative Sib-i was unable to block necroptosis in FADD-deficient Jurkat cells even at the high concentration of 50 lM (Fig. 1C) . Importantly, Sib has a very low cytotoxic effect against human peripheral blood leukocytes (PBL) ( Fig. 2A) or human retinal pigment epithelial cells (RPE-1 hTERT) (Fig. 2B ).
Sib blocks necroptotic but not apoptotic cell death
To further analyze Sib inhibitory effect, we compared the ability of Sib and Nec-1 to block necroptosis in murine and human cell lines in vitro. Necroptosis was induced by a wide range of well-described necroptotic stimuli such as TRAIL + zVAD-fmk, TNF + zVADfmk, or FasL + zVAD-fmk in human U937 or mouse L929 sAhFas cells. In all of these models, Sib efficiently blocked necroptosis in a dose-dependent manner, and with an efficacy almost similar to Nec-1 (Fig. 3A) . This efficient protection from necroptosis by Sib was evidenced by measurements of both plasma membrane permeabilization (% of propidium iodide (PI)-positive cells) and intracellular ATP levels (Fig. 3A) . This latter assay highlighted the fact that Sib inhibitory effect appeared at 2.5 lM and was almost complete at 5 lM. Notably and like Nec-1, Sib did not rescue from apoptosis induced by TRAIL, FasL, or staurosporine in Jurkat cells (Fig. 3B,C) , showing that Sib is a selective inhibitor of necroptosis but not of apoptosis. It is to be noted that in a different human cell line resistant to extrinsic apoptosis, the FADD-deficient Jurkat cells, TNF-induced necroptosis can also be prevented by Sib. Conversely, Fas-induced apoptosis in the L929 sAhFas mouse model is not sensitive to Sib (data not shown). Overall, these data evidenced that Sib specificity toward inhibiting necroptosis, but not apoptosis, does not depend upon the stimuli, the cell type, or even the species.
Sib rescues cells from necroptosis even after cell death initiation and allows cell survival and proliferation
In the hypothetical perspective of using Sib as a necroptosis inhibitor in medicine, we tested its activity when administered after, rather than before, necroptosis initiation. In the following experimental setup, Sib or Nec-1 was added at the nontoxic concentration of 10 lM between 1 to 4 h after TNF-dependent necroptosis induction in FADD-deficient Jurkat cells. When added in the first couple of hours following necroptosis induction, Sib promotes an almost complete recovery by decreasing cell death to approximately 10%. When added 3 or 4 h after necroptosis induction, both Sib or Nec-1 treatment rescued necroptotic FADDdeficient Jurkat cells, reducing by a minimum of 50% the number of PI-positive cells (Fig. 4A ). To further refine Sib's potential at preventing cells from a necroptotic wave, a clonogenic assay was performed 24 h after necroptosis induction by TNF + zVAD-fmk in L929 cells in the presence or absence of Sib, Sib-i, Nec-1, or Nec-1s. Eight days later, culture plates were stained with crystal violet and showed that treatment with Sib, Nec-1, or Nec-1s but not with Sib-i allowed the formation of colonies (Fig. 4B) , suggesting that Sib as other well-known necroptosis inhibitors (Nec-1 or Nec-1s), not only protected cells from cell death but also allowed them to survive and proliferate.
Sib is a potent inhibitor of RIPK1
In order to investigate the mechanism of action of Sib and its target, the selectivity of Sib and Sib-i was tested at 10 lM against a panel of 456 kinases including eight lipid kinases in an in vitro competition binding assay (KINOMEscan; DiscoverX, San Diego, CA, USA). RIPK1 was shown to be among the top kinases targeted by Sib as only 0.2% of the initial amount of the kinase was still on the affinity matrix after competition with Sib (Table S1 and blue circle on Fig. 5A ). Sib-i is not a potent interactor of the tested kinases (Fig. 5A ). Death-associated protein kinase-3 (DAPK3) is only poorly affected by Sib-i (32% of the initial amount of kinase is still on the affinity matrix after competition with 10 lM Sib-i, Fig. 5A To further confirm the inhibition of RIPK1 enzymatic activity by Sib, an in vitro autophosphorylation assay using recombinant full-length RIPK1 (GSTtagged) was performed. This assay showed an inhibition of RIPK1 autophosphorylation by Sib in a dose-dependent manner, Sib-i having no effect (Fig. 6A) . The catalytic activity of RIPK1 was also quantified by monitoring the phosphorylation of myelin basic protein (MBP), a known substrate of RIPK1. Consistently, Sib efficiently inhibits the phosphorylation of MBP in a dose-dependent manner with an IC 50 equal to 1.03 lM (Fig. 6B) .
Finally, to characterize the mechanism of RIPK1 inhibition by Sib, we analyzed the effect of increasing the concentrations of ATP (up to 1 mM of cold ATP) on the inhibition of autophosphorylation by 10 lM of Sib. Results obtained show that in the presence of 1 mM cold ATP, the inhibition of the RIPK1 autophosphorylation by Sib was decreased. It suggests an ATP-competitive mechanism of RIPK1 inhibition by Sib (Fig. 6C ). This result was previously described for Nec-1 [6] . Very interestingly, Sib had a very low inhibitory effect on RIPK3 kinase activity with an IC 50 equal to 101.9 lM (Fig. 6D) . Altogether, these data demonstrated that Sib is a specific inhibitor of RIPK1 kinase activity. In agreement with this biochemical activity, Sib was able, with a similar efficacy to Nec-1, to inhibit RIPK1-dependent necroptosis induced by the combination TNF + TAK1i 
Molecular modeling of the RIPK1-Sib complex
To further understand the mechanism of inhibition by the small chemical compound, we studied in silico the RIPK1-Sib complex to establish a possible model of RIPK1 inhibition by Sib. Molecular docking simulations of Sib to RIPK1 kinase and molecular dynamics trajectory computed for the best complex indicated a preferential binding mode similar to the one described for Nec-1s on a site next to the ATP-binding site (Figs 8 and 9 ). Contact residues determined included notably the seven key amino acids (Leu70, Val76, Leu78, Leu90, Asp156, Ser161, and Phe162) (Fig. 8A ) involved in the interaction with necrostatins (see [43] for details on RIPK1-Necrostatins complexes). An exhaustive list of surrounding residues (3.5
A cut-off) also included the amino acids Met67, Lys77, Lys79, Met92, Val134, and Ile154 (Fig. 9 ). Note here that Met92 is the gatekeeper residue of RIPK1 [6] and the catalytic triad residues are Lys45, Glu63, and Asp156 as reported [43] . Sib thus binds in the 'back' pocket of ). In L929 sAhFas cell line, the same zVAD-fmk pretreatment was followed either with a TNF (10 ngÁmL
À1
) or an Ig-FasL (200 ngÁmL À1 ) 16-h treatment. The percentage of cell death was determined by propidium iodide staining using flow cytometry (upper panels) (n = 3, mean AE SEM, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001). Intracellular ATP levels (lower panels) were measured with the CellTiter-Glo â Luminescent Cell Viability Assay (n = 3, mean AE SEM, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001). Apoptosis was induced in Jurkat wild-type cells with either (B) a TRAIL-Flag (10 ngÁmL À1 ) or Ig-FasL (200 ngÁmL À1 ) or (C) staurosporine (100 nM) 18-h treatment. The percentage of cell death was quantified by flow cytometry using propidium iodide staining (n = 3, mean AE SD). Results shown are representative of at least three independent experiments.
RIPK1 between the DLG motif and the gatekeeper. Despite the presence of a canonical H-bond donor/ H-bond acceptor motif, Sib, like Nec-1s, does not appear to bind to the hinge region, at least in this conformation of the protein (Fig. 8B,C) .
In contrast, the inactive compound Sib-i did not contact the C-lobe region of RIPK1 (Fig. 9) . Comparison between the contact residues predicted for active compounds (Sib and Nec-1s) and inactive compound (Sib-i) did indicate the position of a good inhibitor that should promote hydrophobic interactions with the long helix defined by residues from Pro111 to Lys132, thus locking the conformation of the enzyme by reducing the mobility of the two main subdomains of the kinase toward each other (Fig. 9) .
Sib protects mice from concanavalin A-induced hepatitis
The identification of Sib as a specific necroptosis and RIPK1 inhibitor as Nec-1 prompted us to test this compound in a murine model of immune-dependent hepatitis induced by concanavalin A treatment. In this model, we have previously demonstrated a protective effect of an intravenous injection of Nec-1 or Nec-1s against concanavalin A-induced hepatitis [22, 25] . Here, we studied the protective effect of an intraperitoneal injection of 3 mgÁkg À1 Sib or 6.25 mgÁkg À1 Nec-1s 1 h before an intravenous injection of 12 mgÁkg À1 concanavalin A. Pretreatment with either Sib or Nec-1s protected mice from concanavalin A-induced hepatotoxicity by significantly decreasing serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels measured 24 h after treatment (Fig. 10A) . Moreover, Sib or Nec-1s significantly decreased liver damage by reducing the size of perivascular and parenchymal zones of necrosis stained with hematoxylin and eosin (Fig. 10B, see arrows) and the percentage of necrotic area (Fig. 10C ). In accord with the protection afforded by Sib or Nec-1s, the loss of mouse body weight / calmodulin-dependent protein kinases; CK1, cell kinases 1 (originally known as casein kinase 1); STE, STE kinases (homologs of yeast STErile kinases); TKL, tyrosine kinases-like; TK, tyrosine kinases. Each kinase tested in the assay panel is marked with a circle. The hit kinases reported are marked with a red circle, except RIPK1 which is marked with a blue circle. 0% represents the higher affinity, whereas small green dots indicate that at the tested concentration of molecule (here 10 lM), Sib or Sib-i cannot bind significantly to the kinase (as over 35% of the tested kinase are still on the affinity matrix after competition with the tested compound). For RIPK1, only 0.2% of the initial amount of kinase is still on the affinity matrix after competition with 10 lM Sibiriline (the full list of results for Sibiriline is reported in Table S1 ). Selectivity Score (reported on the figure as S-Score) is a value related to compound selectivity. It is calculated by dividing the number of kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant variants. S-Score(35) = (number of nonmutant kinases with %Ctrl < 35)/(number of nonmutant kinases tested). Images were generated using TREEspot TM Software Tool and reprinted with permission from KINOMEscan induced by concanavalin A treatment was significantly reduced by Sib or Nec-1s pretreatment (Fig. 11) . Altogether these data suggest that 3 mgÁkg À1 Sib had an almost comparable efficacy to 6.25 mgÁkg À1 Nec-1s in protecting mice against concanavalin A-induced hepatitis.
Discussion
By using a cellular screen and a unique noncommer- [44] . Sib was also able to inhibit TRAIL-or FasL-induced necroptosis but not apoptosis regardless of the human or murine cell line origin. Protection from necroptotic cell death was obtained at 1-5 lM concentration of Sib in our diverse cellular systems, suggesting a large therapeutic window for potential clinical application. Moreover, protection from necroptosis has been afforded by Sib up to 4 h after the induction of death, which could allow a therapeutic potential in the case of cardiac infarction or stroke.
Regarding the mode of action underlying necroptosis inhibition by Sib, a KINOMEscan competition binding assay at DiscoverX (456 kinases and activated mutant kinases) was performed and showed that RIPK1 was the top kinase inhibited by Sib. In contrast to Nec-1 which did not bind to RIPK2 and RIPK4 [45] , Sib bound to RIPK4 to a certain extent (Table S1 ). We showed in this study that the kinase activity of RIPK3 is only poorly affected by Sib (approximately 100 times less potently inhibited compared to RIPK1). The KINOMEscan also revealed that JAK2, PDGFRb, KIT, and KIT (V559D) are other major kinases targeted by Sib. Chemical synthesis of Sib analogs, notably driven by the molecular docking reported in this study, would be necessary to improve the selectivity of this compound. As expected, no kinase was efficiently targeted by the inactive counterpart, Sib-i. We also determined a K d binding constant of Sib for RIPK1 of 218 nM, whereas the K d of Sib-i was greater than 30 000 nM. The in vitro competitive assay used for both K d study and kinase profiling is based on an active site/ligand binding technology developed by DiscoverX (Fremont, CA, USA): it can detect the effect of compounds that bind the kinase active site and directly (sterically) or indirectly (allosterically) prevent kinase binding to one immobilized ligand. The majority of kinase inhibitors developed to date target the ATP-binding site. Based on the selectivity reported for Sib, we hypothesized that Sib also targets the ATP-binding site of RIPK1. We showed here that ATP competes with Sib for the inhibition of RIPK1 autophosphorylation (Fig. 6C) . Such result was already described for Nec-1 [6] , suggesting some similarities in the mode of action between Sib and Nec-1. In silico molecular modeling and docking studies highlighted these similarities. To understand the interaction mode of Sib with RIPK1, molecular docking was performed based on the cocrystal structure of RIPK1 with Nec-1s (PDB: code 4ITH). The predictive binding mode was shown on Fig. 8 . As was the case for Nec-1s, Sib was located in the hydrophobic 'back' [32] pocket between the N-lobe and C-lobe of the RIPK1 kinase domain, interacting with both the DLG motif and the gatekeeper. This pocket is formed by a number of residues including Leu70, Val76, Leu78, Leu90, Asp156, Ser161, and Phe162 (see [43] for Necrostatin-1, a well-described inhibitor of RIPK1, was used as an internal control. Coomassie staining was performed in order to estimate the total amount of protein loaded on polyacrylamide gel. Autophosphorylated RIPK1 band was visualized on radiographic film. Assays were performed at least two times, and similar results were obtained each time. The representative images are shown: (B) Sibiriline inhibits the catalytic activity of RIPK1. GST-RIPK1 full length produced by baculovirus in Sf9 insect cells was assayed in the presence of increasing concentrations of Sibiriline with myelin basic protein, MBP, as a substrate. Kinase activities are expressed in % of maximal activity, i.e., measured in the absence of inhibitor. The value marked with a circle corresponds to 10 lM Nec-1s (n = 3, mean AE SD). (C) High concentration of ATP has an effect on the inhibition of RIPK1 autophosphorylation by Sibiriline. The cold ATP (0.25 or 1 mM) was used to study the competition with Sibiriline. These assays are similar to those described in (A). Necrostatin-1, a known ATPcompetitive inhibitor of RIPK1, was used as an internal control. % of RIPK1 activity inhibition is calculated through a ratio with DMSO (-), as a 0 percent reference. The normalization between samples was performed using the quantification of proteins. (D) No effect of Sibiriline on the catalytic activity of RIPK3. GST-RIPK3 full length produced by baculovirus in Sf9 insect cells was assayed in the presence of increasing concentrations of Sibiriline with myelin basic protein, MBP, as a substrate. Kinase activities are expressed in % of maximal activity, i.e., measured in the absence of inhibitor. The value marked with a circle corresponds to 10 lM of GSK'872, a reference RIPK3 inhibitor (n = 3, mean AE SD). the C-lobe also appear to be an important element for successful inhibition. Our results suggest that Sib shares characteristics of the type II kinase inhibitor class, which target the inactive enzymatic conformation, with the caveat that it does not interact with the hinge region, despite its H-bond donor-H-bond acceptor motif. As the description of the druggability of necroptosis [4] , numerous chemobiological studies have led to the discovery of molecules that can bind to the catalytic site of RIPK1 [37] . As examples, compounds characterized by a GlaxoSmithKline group include notably pyrrolo[2,3 b]pyridine-based derivatives [30] . Interestingly, and similar to the putative mechanism of Sib described here, these small chemical compounds also share all characteristics of the type II kinase inhibitor class. This class of compounds is believed to perturb the Phe side chains of the catalytic site inwards to obstruct the ATP-binding cleft. As Nec-1 or Nec-1s has already been shown to protect mice from concanavalin A-induced hepatitis [22, 24, 25] , we tested the effect of Sib in this model of murine hepatitis. Pretreatment of mice with 3 mgÁkg
À1
Sib has almost the same protective effect against concanavalin A-induced hepatitis than pretreatment of mice with 6.25 mgÁkg À1 Nec-1s, by decreasing serum AST/ALT levels and liver injury. Sib seems to have no toxic adverse effect as this compound allowed mice to recover some weight after concanavalin A treatment. Altogether these data demonstrated efficacy of Sib in vivo which make Sib to be a highly promising template for lead optimization.
Materials and methods
Cell lines and culture conditions 
Chemicals and biological compounds
Recombinant human Flag-tagged TRAIL (TRAIL-Flag) and zVAD-fmk were obtained from Enzo Life Sciences (Villeurbanne, France). Necrostatin-1 (Nec-1) and necrostatin-1s (Nec-1s) were from Calbiochem (VWR International, Fontenay-sous-Bois, France). The TAK1 kinase inhibitor, NP-009245, was from AnalytiCon Discovery GmbH (Postdam, Germany). Anti-Flag M2 IgG1 antibody, cycloheximide (CHX), and PI were obtained from Sigma-Aldrich (St Quentin-Fallavier, France). TNFa were obtained from Invitrogen/ Thermo Fisher Scientific. This TNF was used in the screen of new necroptosis inhibitors. Recombinant human TNFa was also produced and purified to at least 99% homogeneity at VIB Protein service facility (Ghent, Belgium). It has a specific biological activity of 6.8 9 10 7 IUÁmg À1 and was used at [46] , a solution of 3-picoline (200 mg, 2.2 mmol, 1 eq) in anhydrous THF (10 mL) was added dropwise to a solution of LDA (freshly prepared by adding nBuLi (1.5 mL, 2.5 M solution in hexanes, 3.9 mmol) to diisopropylamine (0.54 mL, 3.9 mmol) in anhydrous THF (10 mL)) at 0°C under argon atmosphere. The orange mixture was stirred for 20 min before dropwise addition of a solution of 4-methoxybenzonitrile (316 mg, 2.2 mmol, 1 eq) in anhydrous THF (10 mL). After 1 h at 0°C, more LDA solution in THF (10 mL, 3.9 mmol, prepared as above) was added dropwise and the reaction was slowly warmed to RT over 1 h before being heated to reflux in a water bath for 2 h. After cooling, the yellow solution was quenched carefully with saturated NH 4 Cl (10 mL) and water (40 mL) was added. The precipitate was filtered, washed with diethyl ether and water, dried under vacuum to afford 2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine as a light yellow solid (327 mg, 68%). Analytical data are in accordance with the literature. 2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (100 mg, 0.44 mmol) was suspended in anhydrous dichloromethane (5 mL) and cooled to À78°C. Boron tribromide (1.3 mL of 1 M solution on dichloromethane, 1.3 mmol, 3 eq) was added dropwise and the dark red mixture was stirred for 16 h while warming to RT. The reaction was carefully quenched with water, dichloromethane (10 mL) was added, and the solid was dissolved by addition of 1 M sodium hydroxide (15 mL). After stirring for 10 min, the aqueous phase was washed with dichloromethane (2 9 10 mL) and the pH was adjusted to 5 with 1 M hydrochloric acid. The resulting precipitate was filtered, washed with water, and dried under vacuum to obtain a tan solid (68 mg, 74%). . Synthesis of the inactive derivative Sib-i has been described previously [47] .
Cell-based screening assay for characterization of necroptosis inhibitors
The details of the cell-based assay used to screen a library of small chemical compounds have been described in Miao and Degterev [39] . The Jurkat FADD-deficient I 2.1 cell line was maintained in RPMI 1640 medium (Gibco/Thermo Fisher Scientific, Carlsbad, CA, USA) containing Glutamax and 15% fetal calf serum (Eurobio). Necroptosis was induced by addition of 10 ngÁmL À1 of human recombinant TNF-a (Invitrogen/Thermo Fisher Scientific). Necrostatin-1 (Nec-1; Calbiochem) was used as model necroptosis inhibitor. Cells were maintained in 75 cm 2 flask and passaged every 2 or 3 days.
Chemical collections analyzed were formatted in 96-well plates with 80 molecules per plate at 10 mM in 100% DMSO. For each collection plate, two cell plates were seeded (one treated with TNF-a and the other one without TNF-a). Cells were seeded at 20 000 cells per well, in 40 lL of medium, in a 96-well clear, flat bottom plate (CytoOne, Starlab) before treatment. Then, 40 lL of medium with or without TNF-a at 25 ngÁmL À1 was added to all wells in the corresponding plate. Immediately after TNF-a addition, 20 lL of diluted compound at 50 lM was added to the plates. Final concentration of each chemical compound was 10 lM at 0.1% DMSO. Eight positive (Nec-1 at 10 lM final) and eight negative (DMSO) controls were used in each plate to validate the assay. Cells were incubated at 37°C, 5% CO 2 for 24 h before performing MTS viability assay, described hereafter. Compounds were diluted before treating cells. Liquid handling was performed using the Nimbus Microlab liquid handler (Hamilton Robotics, Bonaduz, Switzerland) under microbiological safety workbench. The stock solutions of compounds at 10 mM were diluted directly in culture medium to obtain a solution at 50 lM before treating cells. At the end of treatment, mice were sacrificed (vehicle, n = 5; Sib, n = 4; Nec-1s, n = 4; vehicle + concanavalin A, n = 10; Sib + concanavalin A, n = 13; Nec-1s + concanavalin A, n = 10). (A) Serum levels of AST and ALT were determined at 24 h postconcanavalin A injection as described in Materials and methods. Mean AE SEM *P < 0.05 and **P < 0.01. (B) Hematoxylin and eosin-stained liver sections were shown. Scale bars represent 500 lm. (one picture representative for each group of mice). (C) Percentage of liver necrosis was determined 24 h after concanavalin A treatment in each group (vehicle + concanavalin A, n = 6; Sib + concanavalin A, n = 6; Sib-i + concanavalin A, n = 6) as described in Materials and methods. Mean AE SEM *P < 0.05 and **P < 0.01. 
Cell death assays
Clonogenic assay
After treatment with TNF/zVAD-fmk in the presence or absence of inhibitory compounds (Sib, Sib-i, Nec-1, or Nec-1s) as described above, L929 cells were seeded out in an appropriate dilution, here 1000 cells per well (in six-well plates), and allow for 8 days to form colonies. The subsequent colonies were fixed with ice cold methanol and stained with crystal violet (50% ethanol).
RIPK1 and RIPK3 kinase assays
Human RIPK1 full-length GST-tagged was expressed by baculovirus in Sf9 insect cells (product #R07-10G; SignalChem, Richmond, CA, USA). The protocol used to detect the enzymatic activity is adapted from Degterev et al. [6] . Fig. 11 . Sibiriline reduces the loss of mouse body weight induced by concanavalin A treatment. C57Bl/6 WT mouse body weights were determined 24 h post-treatment in each group (vehicle, n = 5; Sib, n = 4; Nec-1s, n = 4; vehicle + concanavalin A, n = 10; Sib + concanavalin A, n = 13; Nec-1s + concanavalin A, n = 10).
Mean AE SEM *P < 0.05. ) for 16 h. Concentration of cellular ATP was measured using CellTiter-Glo Ò Luminescent Cell viability assay (Promega) according to the manufacturer's instruction and as previously described [22] . ATP concentration was expressed as %/NT AE SD.
Kinase binding assays
Analysis of cell death and caspase-3 activation
Molecular docking
In order to complete the RIPK1 structure available from PDB structures, we performed homology modeling of full RIPK1 protein, notably for the completion of the missing residues. The selected template was ITHJ_B as only loop 177 REVDGTAKKNGG 188 was missing in this structure.
Homology modeling did not seem reliable because it did not propose any structuration of this loop despite PSSPred results predicting that a majority of residues should be involved in alpha-helix secondary structure. PEPFold abinitio method allowed us to model the loop efficiently and finally enabled us to complete the RIPK1 model for molecular docking computations. Next, a normal mode analysis (NMA) was achieved with ElNemo program to modulate the RIPK1 conformations available from the initial model, improving the variety of protein structures that will be used during docking by the addition of two more models for RIPK1 after modes selection (following ElNemo standard validation of essential modes). The final three models of RIPK1 were used as biological target (receptor) for the exploration of possible association modes with compounds Nec-1s, Sib, and Sib-i. Docking calculations were performed by using the standard protocol proposed in the VINA implementation of YASARA suite (global docking, 1000 runs per target/per compound). Results have been clusterized, thanks to the g cluster command of the Gromacs program (Jarvis-Patrick method). After ranking of the poses, the best positioning of the ligand toward the receptor (energy criteria) was submitted to a short molecular dynamics simulation in water for 10 ns in order to improve the model of compound-RIPK1 complex. Final models were obtained after energy minimization after checking that the ligand was stable during the MD trajectory. Ligand-contacting residues were detected using a 3.5 A cut-off distance and pharmacophores were derived from a standard analysis by using Ligand Scout program.
Concanavalin A-induced hepatitis
Seven-to nine-week-old female C57Bl/6 WT mice were purchased from Janvier (Le Genest St Isle, France). Concanavalin A was provided by Sigma-Aldrich and diluted at 12 mgÁkg À1 in PBS/5% DMSO (vehicle). C57Bl/6 WT mice were pretreated for 1 h with intraperitoneal administration
